Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Telcyta: Interim Phase II data

In an ongoing Phase II trial of Telcyta plus carboplatin 54%

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE